Teleflex Q3 Adjusted EPS of $2.63 Crushes $1.90 Consensus
TFX sits 50% above its 52-week low of $100.18.
Summary
Teleflex beat the Street by a wide margin: adjusted EPS of $2.63 against a $1.90 consensus, with the analyst range topping out at $2.04. Revenue of $567.78 million edged past the $565.35 million expected, though it fell 37.8% year over year — the drop reflects the completed OEM divestiture, not organic weakness. Reported EPS was $1.30 and net income $54.29 million. This follows the 8-K filed earlier today that showed Q3 adjusted EPS up 39.2% and raised 2026 adjusted EPS guidance to $7.50-$7.75, plus the first formal continuing-operations guide of $2.84-$3.09. The stock is trading near its 52-week high of $156.67 after gaining 19.9% this quarter, so the beat is largely priced in; the $250 million accelerated share repurchase funded by OEM sale proceeds remains the other lever on the share count.
At the time of this announcement, TFX was trading at $150.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $6.4B. The 52-week trading range was $100.18 to $156.67. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.